Company Overview
About Altay Therapeutics
Altay Therapeutics is a Cambridge, Massachusetts-based biotechnology company — backed by Y Combinator (W20) with $6.71 million raised including a $3 million seed round — developing first-in-class small molecule therapeutics that target transcription factors, historically considered "undruggable" proteins due to their lack of conventional binding sites, for rare genetic diseases and oncology indications. Founded in 2019, Altay's lead programs focus on facioscapulohumeral muscular dystrophy (FSHD) — a rare, progressive muscle disease affecting 1 in 8,500 people with no approved treatments — and cancer targets where transcription factor dysregulation drives tumor growth.
Business Model & Competitive Advantage
Altay's transcription factor inhibition platform addresses one of the fundamental challenges in drug discovery: transcription factors are proteins that regulate gene expression and are frequently mutated or overactivated in disease, but their flat, featureless binding surfaces have resisted conventional small molecule drug design for decades. Altay's approach uses proprietary computational modeling and medicinal chemistry to identify cryptic binding sites and design small molecules that disrupt protein-protein interactions or DNA binding of disease-relevant transcription factors. For FSHD specifically, the disease is driven by toxic expression of the DUX4 transcription factor — inhibiting DUX4 expression or activity represents the mechanistic target that Altay's lead compounds address.
Competitive Landscape 2025–2026
In 2025, Altay Therapeutics competes in the rare disease and oncology drug development market with Fulcrum Therapeutics (FSHD-focused, NASDAQ: FULC, losmapimod for FSHD), Arrowhead Pharmaceuticals (RNA interference for rare diseases), and transcription factor-focused startups for drug development funding and rare disease positioning. FSHD's unmet medical need (progressive muscle weakness, no approved treatment, large untreated patient population) creates orphan drug designation potential and expedited FDA review pathways. Y Combinator's W20 biotech backing connects Altay with the life sciences investor community for future Series A fundraising. The 2025 strategy focuses on completing lead optimization for the FSHD program, generating clinical candidate data package for IND application filing, and establishing partnerships with academic medical centers for natural history data access.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Altay Therapeutics is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Compare Altay Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Altay Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Altay Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Altay Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →